A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.

Trial Details

NCT ID
NCT07540572
Phase
PHASE1 / PHASE2
Sponsor
IDEAYA Biosciences
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • IDE574
  • Fulvestrant injection
Locations (sample)
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Lake Success, New York, United States|40.77066,-73.71763
  • Austin, Texas, United States|30.26715,-97.74306
  • Dallas, Texas, United States|32.78306,-96.80667
  • Fort Worth, Texas, United States|32.72541,-97.32085

Key Eligibility Criteria

  • Archival Tissue sample for testing
  • Part 1A - Participants with advanced or metastatic ER+, HER2- breast cancer, NSCLC, CRPC, and MSS colorectal adenocarcinoma who have progressed on/…
  • Parts 1B, 2A and 2B: Participants with ER+, HER2- breast cancer who have progressed after at least 1 prior line of treatment with an endocrine ther…
  • Female participants with ER+, HER2- breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to unde…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →